180 related articles for article (PubMed ID: 1358427)
1. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma.
Sato K; Moriyama M; Mori S; Saito M; Watanuki T; Terada K; Okuhara E; Akiyama T; Toyoshima K; Yamamoto T
Cancer; 1992 Nov; 70(10):2493-8. PubMed ID: 1358427
[TBL] [Abstract][Full Text] [Related]
2. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
[TBL] [Abstract][Full Text] [Related]
3. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2 gene product-like expression in urothelial carcinomas of the human bladder. Its value as a prognostic indicator in superficial tumors.
Serio G
Pathologica; 1991; 83(1086):413-20. PubMed ID: 1686491
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer.
Lipponen P
Eur J Cancer; 1993; 29A(5):749-53. PubMed ID: 8097100
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of c-erbB-2 oncogene product and epidermal growth factor receptor expression in human urinary bladder carcinomas.
Asamoto M; Hasegawa R; Masuko T; Hashimoto Y; Ueda K; Ohtaguro K; Sasaki S; Washida H; Fukushima S
Acta Pathol Jpn; 1990 May; 40(5):322-6. PubMed ID: 2203226
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB-2 protein, neuron-specific enolase and DNA flow cytometry in locally advanced transitional cell carcinoma of the urinary bladder.
Berner A; Jacobsen AB; Fosså SD; Nesland JM
Histopathology; 1993 Apr; 22(4):327-33. PubMed ID: 8099896
[TBL] [Abstract][Full Text] [Related]
8. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
[TBL] [Abstract][Full Text] [Related]
9. c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder.
Swanson PE; Frierson HF; Wick MR
Mod Pathol; 1992 Sep; 5(5):531-6. PubMed ID: 1364264
[TBL] [Abstract][Full Text] [Related]
10. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
11. Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Naruse K; Yamada Y; Nakamura K; Aoki S; Taki T; Zennami K; Katsuda R; Watanabe M; Nishikawa G; Itoh Y; Mitsui K; Hibi H; Honda N
Oncol Rep; 2010 Jun; 23(6):1577-83. PubMed ID: 20428812
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
[TBL] [Abstract][Full Text] [Related]
13. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
14. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
Lipponen P; Eskelinen M
Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
[TBL] [Abstract][Full Text] [Related]
15. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
16. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics.
Tabriz HM; Olfati G; Ahmadi SA; Yusefnia S
Asian Pac J Cancer Prev; 2013; 14(8):4539-43. PubMed ID: 24083698
[TBL] [Abstract][Full Text] [Related]
18. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical localization of c-erbB-2 protein in transitional cell carcinoma of the urinary bladder.
Coombs LM; Oliver S; Sweeney E; Knowles M
J Pathol; 1993 Jan; 169(1):35-42. PubMed ID: 8094432
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
